Table 3.

ANKRD1 expression levels in lung specimens changed after EGFR-TKI therapy.

No.	Gender	EGFR mutation	EGFR-TKIs Therapy		Score of Immunostaining (%)
					Baseline	After EGFR-TKI	Fold change
1	Male	L858R	Gefitinib	3 months	78	75	0.96
2	Female	L858R	Afatinib	5 months	70	84	1.2
3	Male	Del19	Gefitinib Erlotinib Afatinib	5 months 4 months 4 months	36	84	2.3
4	Female	Del19	Gefitinib	22 months	1	98	98
5	Female	Del19	Gefitinib	22 months	5	88	17.6
6	Female	Del19	Gefitinib Erlotinib	10 months 24 months	1	100	100
7	Male	Del19	Gefitinib Erlotinib Afatinib	34 months 4 months 3 months	0	88	>100
8	Female	Del19	Erlotinib	50 months	39	78	2.0
9	Male	Del19	Gefitinib Afatinib	48 months 4 months	13	100	7.7
10	Female	Del19	Gefitinib Afatinib	58 months 12 months	25	62	2.5